What is the 13F Pro Quality Score for REGN?

13F Pro ranks REGENERON PHARMACEUTICALS, INC. (REGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View REGN's current score at https://13fpro.ai/company/REGN (free sign-up required for the full ranking).

Which hedge funds own the most REGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of REGN include BlackRock,, VANGUARD CAPITAL MANAGEMENT, DODGE & COX. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/REGN as soon as new 13F filings post.

Where does 13F Pro source REGN data?

All REGENERON PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. REGENERON PHARMACEUTICALS, INC. files with the SEC under CIK 872589. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is REGN in?

REGENERON PHARMACEUTICALS, INC. (REGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives REGN's revenue?

Per REGENERON PHARMACEUTICALS, INC.'s latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: Collaboration revenue ($2,455.0M, +$730.7M YoY (Sanofi)); Sanofi ($2,174.3M, +$730.7M YoY); Bayer ($276.2M, -$138.8M YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/REGN.

What are REGN's largest expenses?

REGENERON PHARMACEUTICALS, INC.'s latest 10-Q reports these as the largest expense items: Research and development ($1,631.6M, +$209.9M YoY); Selling, general, and administrative ($662.1M, +$27.9M YoY); Cost of goods sold ($360.7M, +$85.1M YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is REGN research updated on 13F Pro?

REGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

REGENERON PHARMACEUTICALS, INC.(REGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 872589 REGN stock profile & AI dashboard →

13F Pro Quality Score

71.0/100

Rank #201 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

54.7/100

Profitability

83.4/100

Balance Sheet

87.1/100

Earnings Quality

63.0/100

Free Cash Flow

77.9/100

Institutional Flow

78.9/100

Revenue Scale

90.6/100

Dilution Risk

20.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why REGN Scores 71/100

exact factor attribution · 2026-09-11

REGN's composite is driven by scale and profitability, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.1 pts

91th pct

Profitability

+5.0 pts

83th pct

Free cash flow

+4.2 pts

78th pct

Capital efficiency

+3.7 pts

87th pct

Institutional flow

+1.4 pts

79th pct

Earnings quality

+1.3 pts

63th pct

Revenue growth

+0.9 pts

55th pct

Earnings growth

-0.2 pts

45th pct

Shareholder dilution

-1.5 pts

21th pct

Latest change (2026-08-01): 75 → 70 · ↓ Institutional flow 76→22; ↓ Earnings growth 57→40

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

REGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for REGENERON PHARMACEUTICALS, INC. (REGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores REGN at 71.0/100 on a 32-signal composite quality model, placing it at rank #201 of 2,961 stocks — the top 10% of the AI-ranked universe. REGN scores in the top quartile across revenue scale (90.6), balance sheet strength (87.1), profitability (83.4). Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), REGENERON PHARMACEUTICALS, INC. reports quarterly revenue of $4.3B, net income of $1.3B, an operating margin of 30.1%. Top institutional holders of REGN by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, DODGE & COX, based on the most recent SEC filings. REGN trades on the Nasdaq exchange and files with the SEC under CIK 872589. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENERON PHARMACEUTICALS, INC. directly from SEC EDGAR. REGENERON PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 67 and 89 since 2021, currently 71.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about REGENERON PHARMACEUTICALS, INC.

Quirks, history, and lore behind REGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · large-cap · listed on Nasdaq · headquartered in New York State.
2
The Numbers
Annual revenue around $14 billion, built almost entirely on a handful of blockbuster antibody drugs — a remarkably concentrated but lucrative portfolio.
3
The History
Founded in 1988 by two scientists who met at Cornell, it spent years as a pure research outfit before its first drug approval made it a Wall Street darling.
4
The Secret
Its entire drug pipeline is built around a proprietary mouse model engineered to produce human antibodies — essentially outsourcing drug discovery to a very special rodent.
5
The Lore
Its eczema drug Dupixent became one of the fastest-selling medicines in history, and during COVID-19 its antibody cocktail was famously given to a certain U.S. president.
6
The Giveaway
This Hudson Valley biotech gave the world Dupixent, Eylea, and a COVID treatment — all born from the same Tarrytown lab that turns mice into medicine-making machines.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving REGN's Business? Latest 10-Q Breakdown

✓ 46/46 datapoints verified

AI-extracted from REGENERON PHARMACEUTICALS, INC.'s 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue reached $4,290.7M as Sanofi collaboration revenue jumped $730.7M on Dupixent, offsetting a 45% decline in U.S. EYLEA sales; net income fell to $1,296.9M.

Biggest Revenue Drivers

Collaboration revenue$2,455.0M+$730.7M YoY (Sanofi)

Higher profits primarily associated with an increase in Dupixent net product sales

Net product sales$1,642.4M+$11.4M YoY

EYLEA HD and Libtayo volume gains offset by EYLEA declines from competitive pressures and patient transition

Biggest Revenue Drivers

Total revenue: $4,290.7M+$615.1M YoY

Collaboration revenue$2,455.0M+$730.7M YoY (Sanofi)

Higher profits primarily associated with an increase in Dupixent net product sales

Within Collaboration revenue

Sanofi$2,174.3M+$730.7M YoY

Regeneron's share of profits $2,032.6M, 33% of Dupixent and Kevzara net product sales of $6,204.1M

Bayer$276.2M-$138.8M YoY

Lower profits primarily associated with a decrease in EYLEA sales outside the United States

Net product sales$1,642.4M+$11.4M YoY

EYLEA HD and Libtayo volume gains offset by EYLEA declines from competitive pressures and patient transition

Within Net product sales

Total EYLEA HD and EYLEA - U.S.$1,008.5M-$139.0M YoY

EYLEA HD $596.3M on higher volumes; EYLEA $412.2M on lower volumes and lower net selling price

Largest Expense Items

Research and development$1,631.6M+$209.9M YoY

Direct spend rose $85.1M (fianlimab, cenvacibart & amrecibart) and clinical manufacturing costs rose $67.7M

Selling, general, and administrative$662.1M+$27.9M YoY

Higher commercialization-related expenses and headcount costs, offset partly by lower charitable contributions

Cost of goods sold$360.7M+$85.1M YoY

Unabsorbed manufacturing costs from the temporary bulk production interruption in Limerick, Ireland

Cost of collaboration and contract manufacturing$215.8M-$38.8M YoY

Costs of manufacturing drug supplies for collaborators and others

Margins: Gross margin on net product sales fell to 78% from 83%, primarily due to unabsorbed manufacturing costs from a temporary bulk production interruption at Limerick, Ireland; production returned to normal by June 30, 2026.

Watch Items from the Filing

Two distributor customers accounted for 45% and 32% of total gross product revenue in the quarter, versus 52% and 24% a year earlier.
EYLEA U.S. net product sales declined 45% YoY in the quarter to $412.2M on biosimilar and anti-VEGF competition plus transition of patients to EYLEA HD.
Sanofi collaboration revenue, mostly Dupixent profit share, represented 48% of total revenues for the six months ended June 30, 2026, up from 39%.
The Sanofi development balance was fully repaid at June 30, 2026 and will no longer reduce collaboration revenue beginning in the third quarter of 2026.
Acquired in-process R&D expense rose to $127.0M from $10.0M on up-front and opt-in payments, including $50.0M to Parabilis plus $75.0M of its stock.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$4.3B

Net Income

Q2 2026

$1.3B

Free Cash Flow

Q2 2026

$572.8M

Operating Margin

Q2 2026

30.1%

ROIC

Q2 2026

15.3%

D/E Ratio

Q2 2026

0.06

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1.0% YoY

$14.34BFY 2025

FY22 $12.17BFY23 $13.12BFY24 $14.20BFY25 $14.34B

Net Income

+2.1% YoY

$4.50BFY 2025

FY22 $4.34BFY23 $3.95BFY24 $4.41BFY25 $4.50B

Operating Income

-10.3% YoY

$3.58BFY 2025

FY22 $4.74BFY23 $4.05BFY24 $3.99BFY25 $3.58B

EPS (Diluted)

+8.2% YoY

$41.48FY 2025

FY22 $38.22FY23 $34.77FY24 $38.34FY25 $41.48

Total Assets

+7.4% YoY

$40.56BFY 2025

FY22 $29.21BFY23 $33.08BFY24 $37.76BFY25 $40.56B

Total Debt

+0.1% YoY

$1.99BFY 2025

FY22 $1.98BFY23 $1.98BFY24 $1.98BFY25 $1.99B

Op. Cash Flow

+12.6% YoY

$4.98BFY 2025

FY22 $5.01BFY23 $4.59BFY24 $4.42BFY25 $4.98B

Free Cash Flow

+11.3% YoY

$4.08BFY 2025

FY22 $4.42BFY23 $3.88BFY24 $3.66BFY25 $4.08B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$14.34B +1.0%	$14.20B +8.3%	$13.12B +7.8%	$12.17B -24.3%	$16.07B +89.1%	$8.50B
Net Income	$4.50B +2.1%	$4.41B +11.6%	$3.95B -8.9%	$4.34B -46.3%	$8.08B +129.9%	$3.51B
Operating Income	$3.58B -10.3%	$3.99B -1.4%	$4.05B -14.6%	$4.74B -47.0%	$8.95B +150.1%	$3.58B
EPS (Diluted)	$41.48 +8.2%	$38.34 +10.3%	$34.77 -9.0%	$38.22 -46.9%	$71.97 +135.8%	$30.52
Total Assets	$40.56B +7.4%	$37.76B +14.1%	$33.08B +13.2%	$29.21B +14.9%	$25.43B +48.2%	$17.16B
Total Debt	$1.99B +0.1%	$1.98B +0.1%	$1.98B +0.1%	$1.98B +0.1%	$1.98B +0.1%	$1.98B
Operating Cash Flow	$4.98B +12.6%	$4.42B -3.8%	$4.59B -8.4%	$5.01B -29.2%	$7.08B +170.5%	$2.62B
Free Cash Flow	$4.08B +11.3%	$3.66B -5.4%	$3.88B -12.4%	$4.42B -32.2%	$6.53B +225.9%	$2.00B

Get alerted when REGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for REGENERON PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of REGN

BlackRock, Inc.
$5.7B9,113,506 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.1B6,629,759 sh
DODGE & COX
$3.0B4,871,137 sh
STATE STREET CORP
$3.0B4,834,688 sh
Invesco Ltd.
$2.5B3,940,665 sh
JPMORGAN CHASE & CO
$2.4B3,774,199 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.0B3,175,313 sh
FRANKLIN RESOURCES INC
$1.7B2,771,839 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.6B2,625,810 sh
Nuveen, LLC
$1.3B2,019,974 sh

Fund	Value	Shares
BlackRock, Inc.	$5.7B	9,113,506
VANGUARD CAPITAL MANAGEMENT LLC	$4.1B	6,629,759
DODGE & COX	$3.0B	4,871,137
STATE STREET CORP	$3.0B	4,834,688
Invesco Ltd.	$2.5B	3,940,665
JPMORGAN CHASE & CO	$2.4B	3,774,199
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.0B	3,175,313
FRANKLIN RESOURCES INC	$1.7B	2,771,839
GEODE CAPITAL MANAGEMENT, LLC	$1.6B	2,625,810
Nuveen, LLC	$1.3B	2,019,974

Companies Similar to REGN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 42 shared holders

LOOMIS SAYLES & CO L P Capital World Investors National Pension Service

BIIB

BIOGEN INC.

AI score

Very similar · 32 shared holders

Robeco Institutional Asset Management B.V.CAISSE DE DEPOT ET PLACEMENT DU QUEBEC LSV ASSET MANAGEMENT

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 43 shared holders

Robeco Institutional Asset Management B.V.National Pension Service NORDEA INVESTMENT MANAGEMENT AB

Edwards Lifesciences Corp

AI score

Very similar · 31 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC NORDEA INVESTMENT MANAGEMENT AB National Pension Service

ABT

ABBOTT LABORATORIES

AI score

Very similar · 39 shared holders

National Pension Service WORLDQUANT MILLENNIUM ADVISORS LLC PeakShares LLC

SYK

STRYKER CORP

AI score

Very similar · 22 shared holders

NORDEA INVESTMENT MANAGEMENT AB National Pension Service Robeco Institutional Asset Management B.V.

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 28 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Robeco Institutional Asset Management B.V.Epoch Investment Partners, Inc.

MDT

Medtronic plc

AI score

Very similar · 33 shared holders

DODGE & COX Capital World Investors National Pension Service

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put REGN on your watchlist

Track score changes the day REGENERON PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is REGN a good stock to buy?

13F Pro's AI-powered analysis of REGENERON PHARMACEUTICALS, INC. (REGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REGN are available on the REGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. REGN is classified as a large company.

Which hedge funds own REGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REGENERON PHARMACEUTICALS, INC.'s investment landscape.